1. Antimycobacterial activity of the antiinflammatory agent diclofenac sodium, and its synergism with streptomycin
- Author
-
Sujata G. Dastidar, Noton K. Dutta, A. N. Chakrabarty, Asok Kumar, Raja Ray, and Kaushiki Mazumdar
- Subjects
streptomycin ,medicine.drug_class ,não-antibiótico ,Drug resistance ,Pharmacology ,Antimycobacterial ,Microbiology ,Median lethal dose ,Mycobacterium tuberculosis ,estreptomicina ,sinergismo ,Diclofenac ,In vivo ,synergism ,atividade antimicobacteriana ,medicine ,droga antiinflamatória ,diclofenac sodium ,antimycobacterial activity ,biology ,business.industry ,Diclofenac Sodium ,biology.organism_classification ,non-antibiotic ,antiinflammatory drug ,Streptomycin ,diclofenac sódico ,business ,medicine.drug - Abstract
Diclofenac sodium, an antiinflammatory agent, exhibited remarkable inhibitory action against both drug sensitive and drug resistant clinical isolates of Mycobacterium tuberculosis, as well as other mycobacteria. This drug was tested in vitro against 45 different strains of mycobacteria, most of which were inhibited by the drug at 10-25 µg/ml concentration. When tested in vivo, diclofenac, injected at 10 µg/g body weight of a Swiss strain of white mice, could significantly protect them when challenged with 50 median lethal dose of M. tuberculosis H37 Rv 102. According to chi2 test, the in vivo data were highly significant (p
- Published
- 2004
- Full Text
- View/download PDF